reports
- David Nierengarten
- Dennis Pak
- Martin Fan
Moody's Ratings assigns Aa2 rating to preferred shares issued by Nuvee...
Rating Action: Moody's Ratings assigns Aa2 rating to preferred shares issued by Nuveen Municipal High Income Opportunity Fund following mergers. Global Credit Research- 27 Apr 2026. New York, April 27, 2026-- Moody's Ratings has assigned a long-term Aa2 rating to Series 1 Variable Rate Demand Preferred Shares issued by Nuveen Municipal High Income Opportunity Fund following the merger of three other Nuveen closed-end funds into the fund.
- David Nierengarten
- Dennis Pak
- Martin Fan
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro...
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reductionTrial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Te...
Codexis to Report First Quarter 2026 Financial Results on May 7
Codexis to Report First Quarter 2026 Financial Results on May 7 REDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the first quarter of 2026 on Thursday, May 7, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live ...
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that an abstract has been accepted for publication at the upcoming 2026 ASCO Annual Meeting along with a corresponding poster presentation. The 2026 ASCO Annual Meeting will be held from May 2...
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding La...
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it h...
- Wedbush Research
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ARDX ARDELYX INC
2303 UNITED MICROELECTRONICS CORP.
ANAB ANAPTYSBIO INC.
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SMCI SUPER MICRO COMPUTER
PASG INC.
TVTX PASSAGE BIO
SANA TRAVERE THERAPEUTICS INC
STX SANA BIOTECHNOLOGY
TCRX SEAGATE TECHNOLOGY HLDGS PLC
GFS TSCAN THERAPEUTICS INC
ARTV GLOBALFOUNDRIES INC
SYRE ARTIVA BIOTHERAPEUTICS INC
USAR SPYRE THERAPEUTICS INC.
TRAX V USA RARE EARTH INC
FIRST TRACKS BIOTHERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Martin Fan
Anaptys Completes Separation of First Tracks Biotherapeutics and Now E...
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. A...
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label...
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026 STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the AACR Meeting 2026. The abstract is shown below and the poster being presented today can be seen and downloaded a...
- Wedbush Research
TSLA TESLA INC
SRPT SAREPTA THERAPEUTICS INC.
NVCR NOVOCURE LTD.
NKTR NEKTAR THERAPEUTICS
NCMI NATIONAL CINEMEDIA INC.
MCS MARCUS CORPORATION
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
FATE FATE THERAPEUTICS INC
CNK CINEMARK HOLDINGS INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
ANAB ANAPTYSBIO INC.
OVID OVID THERAPEUTICS
ISR ISORAY
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
STRO SUTRO BIOPHARMA
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
COGT COGENT BIOSCIENCES INC
MP MP MATERIALS CORP (A)
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
TNGX TANGO THERAPEUTICS
TMC INC
CMPX THE METALS COMPANY INC
NUVL COMPASS THERAPEUTICS
LAC. NUVALENT INC
USAR LITHIUM AMERICAS CORP NEW
BBOT USA RARE EARTH INC
EIKN BRIDGEBIO ONCOLOGY THERAPEUTICS INC
EIKON THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Robert Driscoll
- Thomas Yip
- Yun Zhong
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
VALE.N VALE S.A. ADS
MKC MCCORMICK & COMPANY INCORPORATED
GSBD GOLDMAN SACHS BDC INC
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
CTAS CINTAS CORPORATION
CAG CONAGRA BRANDS INC.
BZUN BAOZUN INC SPONSORED ADR CLASS A
GAM GENERAL AMERICAN INVESTORS CO. INC.
SJW SJW GROUP
CULP CULP INC.
SCVL SHOE CARNIVAL INC.
CIA CITIZENS INC. CL A
FUL H.B. FULLER COMPANY
CRT CROSS TIMBERS ROYALTY TRUST
LW LAMB WESTON HOLDINGS INC.
NKE NIKE INC. CLASS B
PAGS PAGSEGURO DIGITAL LTD
FUND ROYCE FOCUS TRUST
FGBI INC.
NMM FIRST GUARANTY BANCSHARES
ENR NAVIOS MARITIME PARTNERS
SVC EDGEWELL PERSONAL CARE COMPANY
AIMD.P SERVICE PROPERTIES TRUST
CNXC AIM4 VENTURES
QFIN CONCENTRIX
VSCO 360 DIGITECH INC
SG VICTORIA'S SECRET & CO
HDB SWEETGREEN INC
IBRX HDFC BANK LTD
BEAT IMMUNITYBIO INC
MEGI HEARTBEAM INC
POCI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
BPRN PRECISION OPTICS CORP INC (MASS)
LPCN BANK OF PRINCETON
HYMC LIPOCINE INC
BETR HYCROFT MINING HOLDING CORPORATION
BNR BETTER HOME & FINANCE HOLDING COMPANY
VVOS BURNING ROCK BIOTECH LIMITED
MESO VIVOS THERAPEUTICS INC
USAU MESOBLAST LIMITED
COE USA URANIUM
COLUMBIA EQUITY TRUST
INC.
- Jonathan Moreland
Greenwich LifeSciences Provides Update on Financing Strategy
Greenwich LifeSciences Provides Update on Financing Strategy STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its financing strategy. The Company's ATM financing vehicle allows the Company to sell its common stock directly into the trading market at market price. The amount raised through...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
GLOB GLOBANT SA
ANAB ANAPTYSBIO INC.
OVID OVID THERAPEUTICS
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
REPL REPLIMUNE GROUP
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
RVMD IDEAYA BIOSCIENCES
TVTX REVOLUTION MEDICINES
NUVB TRAVERE THERAPEUTICS INC
STX NUVATION BIO INC (A)
TASK SEAGATE TECHNOLOGY HLDGS PLC
GFS TASKUS INC
CMPX GLOBALFOUNDRIES INC
EWTX COMPASS THERAPEUTICS
NUVL EDGEWISE THERAPEUTICS INC
TLX NUVALENT INC
TELIX PHARMACEUTICALS LIMITED
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Robert Driscoll
- Thomas Yip
- Yun Zhong
- Jonathan Moreland
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
GSBD GOLDMAN SACHS BDC INC
FMNB FARMERS NATIONAL BANC CORP.
BZUN BAOZUN INC SPONSORED ADR CLASS A
CULP CULP INC.
SCVL SHOE CARNIVAL INC.
WVE WAVE LIFE SCIENCES
TSI TCW STRATEGIC INCOME FUND INC.
CIA CITIZENS INC. CL A
FUL H.B. FULLER COMPANY
CRT CROSS TIMBERS ROYALTY TRUST
LW LAMB WESTON HOLDINGS INC.
VALE. COMPANHIA VALE DO RIO DOCE CEDEAR
NKE NIKE INC. CLASS B
PAGS PAGSEGURO DIGITAL LTD
FUND ROYCE FOCUS TRUST
FGBI INC.
NMM FIRST GUARANTY BANCSHARES
RPAY NAVIOS MARITIME PARTNERS
GO REPAY HOLDINGS (A)
SVC GROCERY OUTLET HOLDING
AHCO SERVICE PROPERTIES TRUST
AIMD.P ADAPTHEALTH
CNXC AIM4 VENTURES
QFIN CONCENTRIX
VSCO 360 DIGITECH INC
SG VICTORIA'S SECRET & CO
TOI SWEETGREEN INC
IPX ONCOLOGY INSTITUTE INC (THE)
HDB IPERIONX LTD
TSM HDFC BANK LTD
IBRX TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
ECAT IMMUNITYBIO INC
POCI BLACKROCK ESG CAP ALLOCATION TR
BPRN PRECISION OPTICS CORP INC (MASS)
LPCN BANK OF PRINCETON
GAM LIPOCINE INC
HYMC GENERAL DE ALQUILER DE MAQUINARIA
BETR HYCROFT MINING HOLDING CORPORATION
VERO BETTER HOME & FINANCE HOLDING COMPANY
BNR VENUS CONCEPT INC
VVOS BURNING ROCK BIOTECH LIMITED
MESO VIVOS THERAPEUTICS INC
USAU MESOBLAST LIMITED
USA URANIUM
Greenwich LifeSciences Provides Update on Patent Claims Potentially Do...
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data. Statistically significant immune ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.